AIM
JAZZ icon

Acrospire Investment Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Acrospire Investment Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-200
Closed -$31K – 724
2017
Q2 		$31K Hold
200
– – 0.03% 1257
2017
Q1 		$29K Sell
200
-1,700
-89% -$221K 0.02% 1374
2016
Q4 		$207K Buy
+1,900
New +$212K 0.09% 337

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Acrospire Investment Management's JAZZ Position: Q3 2017 in Review

Acrospire Investment Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2017, closing a stake of 200 shares — an estimated $31K sold.

Acrospire Investment Management first reported a position in JAZZ in Q4 2016 and held it in 3 quarters. The position peaked at $207K in Q4 2016. 303 funds tracked by Wall St. Rank hold JAZZ as of Q3 2017.

  • Acrospire Investment Management reported no remaining Jazz Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 200 Jazz Pharmaceuticals shares in Q3 2017, an estimated $31K.
  • Acrospire Investment Management first reported a position in Jazz Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Jazz Pharmaceuticals position peaked at $207K in Q4 2016.
  • 303 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.